Compare Pfizer Inc (PFE) vs Prudential PLC (PUK) Price & Performance

Pfizer (PFE) trades at $27.82, up 1.22% with a bullish technical signal from moving averages. The company shows stable revenue around $62-63B with consistent earnings beats in recent quarters. Analysts maintain a $29.40 consensus target with 40% buy ratings. Recent news highlights Pfizer's focus on obesity and oncology pipelines as key growth drivers.

Pfizer offers value with defensive cash flows and dividend stability, though patent cliffs and margin compression present challenges. The stock's current valuation appears reasonable relative to sector peers, with upside potential if pipeline developments succeed. Key risks include competitive pressures and regulatory hurdles for new drug approvals.

PUK trades at $23.88, down 2.93% over 24 hours, amid a bearish technical signal. The company reported strong revenue growth to $27.39B in 2025 and net income of $3.98B, with a net margin of 14.52%. Recent earnings show mixed quarterly results, with two beats and two misses versus expectations. Analyst consensus is moderately bullish, with 50% buy ratings. The firm is executing a strategic overhaul, including a $3B capital rotation plan and exiting certain markets to sharpen focus.

The outlook is cautiously optimistic given solid profitability and strategic initiatives, but near-term headwinds include earnings volatility and bearish technical indicators. Risks involve execution of the restructuring and macroeconomic pressures. The stock presents a value opportunity with a low P/E of 8.28, though investors should weigh the mixed earnings record against growth prospects.